Dataset from A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV-1 Infected Subjects.

This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation
containing two FDA-approved drugs in HIV-infected patients who have not received prior
therapy. This tablet will be taken with one of two FDA-approved drugs as a once-daily
regimen. Study physicians will evaluate subjects to determine if they have certain medical
conditions, laboratory test values, medication use, or drug allergies that would exclude them
from the study.